<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">atp13a4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP13A4</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>ATPase Cation Transporting Member 4</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3q29</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[85365](https://www.ncbi.nlm.nih.gov/gene/85365)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607224](https://www.omim.org/entry/607224)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000119661</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9H0M0](https://www.uniprot.org/uniprot/Q9H0M0)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>P5B-type ATPase, cation transporter</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HP91, KIAA1197</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Salivary glands</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">atp13a4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP13A4</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>ATPase Cation Transporting Member 4</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3q29</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[85365](https://www.ncbi.nlm.nih.gov/gene/85365)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607224](https://www.omim.org/entry/607224)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000119661</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9H0M0](https://www.uniprot.org/uniprot/Q9H0M0)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>P5B-type ATPase, cation transporter</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HP91, KIAA1197</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Salivary glands</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>ATP13A2</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP13A2 (PARK9)</td>
</tr>
<tr>
<td class="label">Disease Association</td>
<td>Kufor-Rakeb syndrome</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>High (basal ganglia)</td>
</tr>
<tr>
<td class="label">Lysosomal Localization</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Mn²⁺, Zn²⁺, polyamines</td>
</tr>
<tr>
<td class="label">Knockout Phenotype</td>
<td>Neurodegeneration</td>
</tr>
</table>
ATP13A4 (ATPase Cation Transporting Member 4) is a member of the P5B-type ATPase family, a group of cation transport proteins that play critical roles in cellular homeostasis and have been increasingly implicated in neurodegenerative diseases. While most extensively studied in the context of its close homolog [ATP13A2](/genes/atp13a2) (also known as PARK9), ATP13A4 represents an important but understudied player in brain metal homeostasis and neuronal function.
The P5B-ATPases constitute a unique family of P-type ATPases that are primarily localized to endolysosomal compartments, where they regulate cation transport across membrane boundaries. This subfamily includes five members in humans: ATP13A1, ATP13A2, ATP13A3, ATP13A4, and ATP13A5, each with distinct expression patterns and cellular functions [1]. ATP13A4 is predominantly expressed in neural tissue and has been linked to various aspects of neuronal health and disease.[@as2020]
ATP13A4 encodes a large transmembrane protein approximately 924 amino acids in length. Like other P-type ATPases, ATP13A4 contains characteristic structural domains [2]:
The transmembrane domain contains key residues involved in cation binding and translocation. Unlike some P5B members, ATP13A4 appears to have偏好 for specific divalent cations, though its exact substrate specificity remains an active area of investigation [3].
ATP13A4 functions as a P-type ATPase, utilizing ATP hydrolysis to transport cations against their electrochemical gradient.[@ojm2018] The transport cycle follows the classical E1-E2 conformational model:
This cycle allows for vectorial transport of cations across membrane boundaries, primarily from the cytosol into the lumen of intracellular compartments.
The substrate specificity of ATP13A4 has been the subject of considerable research. Studies suggest it may transport [divalent cations](/mechanisms/metal-homeostasis-pathway) including:
ATP13A4 exhibits a primarily intracellular distribution with highest concentrations in [endolysosomal compartments](/cell-types/microglia) [5]:
Within the human body, ATP13A4 displays a tissue-specific expression pattern:
The high expression in [brain regions](/brain-regions/hippocampus) associated with memory and cognition, particularly the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus), suggests important roles in higher brain functions and potentially in neurodegenerative diseases.
ATP13A4 has been increasingly implicated in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis through several mechanisms [6]:
Genetic Associations: Copy number variations (CNVs) in the ATP13A4 locus have been associated with increased PD risk. These genomic alterations may lead to either loss or gain of function, though the precise mechanism remains unclear [7].
Overlap with ATP13A2: Given its close homology to ATP13A2 (PARK9), ATP13A4 may partially compensate for ATP13A2 dysfunction. Loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome, a form of early-onset parkinsonism. ATP13A4 could potentially modulate the severity of ATP13A2-related phenotypes.
Lysosomal Dysfunction: As a lysosomal cation transporter, ATP13A4 maintains the ionic environment necessary for proper lysosomal function. Disruption can lead to impaired [autophagy](/mechanisms/autophagy-pathway) and accumulation of damaged proteins, including [alpha-synuclein](/proteins/alpha-synuclein).
Metal Homeostasis: Proper manganese and iron handling in dopaminergic neurons is critical for their survival. ATP13A4 dysfunction may contribute to metal-induced neurotoxicity in the [substantia nigra](/brain-regions/substantia-nigra).
Emerging evidence links ATP13A4 to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis [8]:
Beta-amyloid handling: Lysosomal dysfunction associated with ATP13A4 deficiency may impair the clearance of [beta-amyloid](/proteins/amyloid-beta) plaques. Lysosomes play a critical role in amyloid clearance, and cation transport is essential for their degradative capacity.
Tau pathology: Metal dysregulation is a well-established feature of AD. ATP13A4-mediated zinc and manganese transport may influence tau phosphorylation and aggregation.
Neuroinflammation: P5B-ATPase dysfunction in microglia could exacerbate the [neuroinflammatory response](/mechanisms/microglia-neuroinflammation) characteristic of AD.
ATP13A4 variants have been reported in [hereditary spastic paraplegia](/diseases/hereditary-spastic-paraplegia) (HSP) cases [9]:
ATP13A4 dysregulation has been implicated in:
ATP13A4 participates in a network of protein interactions:
Direct Interactions:
ATP13A4 interfaces with several critical signaling cascades:
ATP13A4 represents a potential therapeutic target in neurodegeneration [10]:
Activators: Small molecules that enhance ATP13A4 activity could:
ATP13A4 expression in peripheral tissues could serve as a biomarker:
While ATP13A4 is not routinely tested in clinical settings:
ATP13A4 assessment may be useful in several clinical contexts:
Key areas of ongoing investigation include:
Understanding ATP13A4 requires comparison with its well-studied homolog ATP13A2:
The functional overlap between these proteins suggests potential compensation, making ATP13A4 an interesting therapeutic target.
Several mouse models have been developed to study P5B-ATPase function:
Experimental systems used to study ATP13A4:
Key experimental techniques:
ATP13A4 shows high conservation across vertebrates:
The P5B-ATPase family expanded during vertebrate evolution:
Population genetic studies reveal:
Based on current knowledge:
The field of P5B-ATPase research is rapidly evolving. Several directions appear particularly promising:
As our understanding of ATP13A4 advances, it may emerge as an important therapeutic target in neurodegenerative diseases. The close relationship to ATP13A2 suggests that lessons learned from ATP13A2 biology can be rapidly translated to ATP13A4.